Background: Blood supply to the thyroid is relatively high when compared to that of liver. Despite this documented metastatic deposit in thyroid remains a rarity. Synchronous nonthyroidal metastatic deposit in thyroid from a lung primary is relatively rare. Metastasis to thyroid portends to poor prognosis, and hence a metastatic deposit has to be excluded in any suspicious lesion of thyroid.
INTRODUCTION
Metastatic deposits in thyroid gland are extremely rare, with autopsy series reporting an incidence of 0.5%-24%. [1, 2] Thyroidectomies for malignancies have yielded only 1.25% of metastatic lesions. [2] Nakhjavani from Mayo clinic in 1966 opined metastasis to thyroid to portend poor prognosis. [3] Adenocarcinoma is the most common to have thyroid metastasis. Diagnosis of metastatic lesions poses dilemma, as fine-needle aspiration for cytology (FNAC) is not always conclusive, and require immunohistochemical (IHC) studies, especially in poorly differentiated tumors. Case reported here posed diagnostic dilemma, in spite of modern imaging and laboratory facilities, stressing the importance of complete, diligent evaluation.
THE CASE
A 63-year-old man, reformed smoker, presented with bilateral neck swelling of 3-month duration. Outside evaluation showed multi-nodular goiter, with bilateral cervical lymphadenopathy. FNAC from thyroid lesion was reported as papillary carcinoma.
Clinical examination showed enlarged, nodular bilateral thyroid lobes, and bilateral cervical level III and IV lymph nodes. Cytology slides reviewed in-house was reported as: "Suggestive of cellular thyroid lesion. However, the possibility of papillary carcinoma thyroid with cystic degeneration could not be ruled out." The patient underwent total thyroidectomy after necessary preanesthetic evaluations, including chest radiograph.
Histopathology and IHC showed neoplastic cells positive for thyroid transcription factor 1 (TTF-1) and carcinoembryonic antigen [ Figures 1 and 2] . Thyroglobulin, calcitonin, and high molecular weight keratin were negative. Out of 42, 38 lymph nodes showed metastasis. With the histological and IHC findings, the final diagnosis considered was, poorly differentiated carcinoma with mucin This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. secretion, even though mucin secretion in these tumors is not described in literature. He was staged pT3N1bMx. Second opinion was sought from renowned pathologists, whose differentials were mucoepidermoid carcinoma, mucinous carcinoma, and metastasis, and concluded that based on clinical and histopathological data mucinous carcinoma of thyroid could be the most likely pathology.
Extrathyroid extension mandated adjuvant radiation and simulation computed tomography (CT) scan for radiotherapy planning, revealed left-sided pleural effusion and posterior pleural-based nodule in the left lung, lower lobe. Subsequent contrast-enhanced CT scan showed well-defined mildly enhancing soft-tissue density lesion with spiculated margins, 2.6 cm × 2.4 cm in posterior basal segment of the left lower lobe. Mild left pleural effusion and multiple enlarged nodes at prevascular, upper and lower paratracheal, para-aortic levels, and bilateral hilar nodes were noted. Guided biopsy from lung lesion [ Figure 3 ] showed papillary neoplasm, positive for TTF1 and cytokeratin-7 (CK7), and negative for thyroglobulin. Histopathological and IHC findings of thyroid and lung lesions matched, and diagnosis of papillary adenocarcinoma of lung with metastases to thyroid [ Figure 4 ] was confirmed.
The patient was planned for chemotherapy using carboplatin-etoposide on which he progressed. Second-line paclitaxel-carboplatin combination and salvage single-agent docetaxel also failed, and he developed superior vena cava obstruction. Supportive symptomatic domiciliary care was opted, and he succumbed within 9 months of initial presentation.
DISCUSSION
About 70%-80% of thyroid tumors are papillary carcinomas, having favorable prognosis even with extensive lymph nodal involvement.
[4] Wada quoted high incidence of recurrence in patients with palpable lymph nodes at presentation, especially in elderly (>45 years). [5] Tissue diagnosis of papillary carcinoma of thyroid by two onco-pathologists, justifies radical thyroid surgery in index case. Virchow in 1871 documented metastatic lesions in thyroid in his autopsy series. [6] Willis, in 1931, observed that [6] despite high arterial blood flow of 560 ml/100 g of tissue per minute, more than half of what entire liver receives; huge disparity exists in reported metastasis to thyroid and that these are not as rare as believed, necessitating thorough pathological evaluation of any thyroid lesion.
Nonthyroidal primaries metastasizing to thyroid is very rare [7] accounting 1.4%-3%. Chung et al. quoted that renal-cell carcinoma tops this list with 48.1% incidence, followed by colorectal with 10.4%. Lung has about 8.3% incidence. Interval between detection of primary disease and metastatic lesion in thyroid was longest in sarcomas (75 months), and shortest in lung malignancies (4.5 months). [7] Synchronous presentation of primary and metastatic lesions in thyroid was observed in renal-cell carcinoma (25 among 69) and lung (15/69). [7] Namad et al. opined that [8] adenocarcinoma of lung is the most common to metastasize to thyroid followed by squamous, small cell and large cell carcinomas. Rare thyroid metastasis from small-cell lung cancer is also reported. [9] Distant metastasis in head and neck malignancy is 7%-23%, [10] and for papillary thyroid cancer is <10%. [11] Features of thyroid cancer predicting aggressive disease are age >45 years, male gender, and aggressive histological factors such as columnar, tall cell, and insular variants of differentiated thyroid cancers. [12] Histopathological diagnosis of thyroid malignancy is challenging. Criteria differentiating malignant lesions are features of aggressiveness, nature of tumor capsule, and invasion of surrounding structures such as thyroid parenchyma, vasculature, and skeletal muscles. [13] IHC studies complement morphological findings. One of the first antibodies used in the diagnosis of thyroid malignancies was Hector Battifora mesothelial antigen (HBME1). [14] Since then an array of markers have been in use. Extensively studied markers are, HBME1, CK19, galectin-3, TTF-1, p53, thyroperoxidase, CD57, CD44v6, Rb-1, and CD56 (NCAM). [15] CD56 is highly specific for papillary carcinoma thyroid. [16] IHC panel for lung includes epithelial markers, CK AE1/AE3 and CK7; neuroendocrine markers chromogranin, synaptophysin, TTF-1 and p53; and mesenchymal markers leukocyte-common antigen and smooth-muscle actin. Primary non-small cell lung cancer is TTF-1 and CK7 positive; and adenocarcinoma CK5/ CK6, CK7, and surfactant protein-A positive. [17] Thyroglobulin differentiates primary thyroid tumor from primary lung lesion. Differentiating metastatic lesion in thyroid from lung is difficult, especially with poor differentiation.
Chest radiograph is usually opted instead of CT scan of thorax in thyroid malignancy workup, though far inferior to CT scan in detecting malignant lung lesions. [18] In index case, chest radiograph before surgery had failed to pick up the lesion resulting in wrong diagnosis [ Figure 5 ]. CT scan of thorax has high sensitivity (73%) and specificity (80%) in detecting lung lesions and remains an important tool in screening lung in head and neck malignancies. [19] This is significant when considering high prevalence of pulmonary Koch's (75/100,000 population), [20] and possibility of synchronous second primary in lung, especially with long smoking history.
CONCLUSION
Although encountered rarely, metastatic lesions in thyroid from nonthyroidal primaries need to be excluded while evaluating thyroid lesions. Probabilities of detecting coexistent lesions should be judiciously weighed against financial constraints while considering imaging modalities, in countries like India.
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